[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Crispr Therapeutics Ag (CRSP)

Crispr Therapeutics Ag (CRSP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,740,663
  • Shares Outstanding, K 96,693
  • Annual Sales, $ 3,510 K
  • Annual Income, $ -581,600 K
  • EBIT $ -534 M
  • EBITDA $ -515 M
  • 60-Month Beta 1.74
  • Price/Sales 1,631.66
  • Price/Cash Flow N/A
  • Price/Book 3.27

Options Overview Details

View History
  • Implied Volatility 63.78% (+0.09%)
  • Historical Volatility 52.72%
  • IV Percentile 59%
  • IV Rank 48.66%
  • IV High 83.16% on 10/15/25
  • IV Low 45.41% on 08/18/26
  • Expected Move (DTE 7) 3.27 (5.67%)
  • Put/Call Vol Ratio 0.25
  • Today's Volume 6,007
  • Volume Avg (30-Day) 4,191
  • Put/Call OI Ratio 0.54
  • Today's Open Interest 76,337
  • Open Int (30-Day) 67,099
  • Expected Range 54.45 to 60.99

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-1.06
  • Number of Estimates 8
  • High Estimate $-0.61
  • Low Estimate $-1.30
  • Prior Year $-1.17
  • Growth Rate Est. (year over year) +9.40%

Price Performance

See More
Period Period Low Period High Performance
1-Month
46.82 +23.28%
on 07/29/26
62.53 -7.70%
on 08/21/26
+10.17 (+21.39%)
since 07/28/26
3-Month
45.89 +25.78%
on 07/28/26
63.45 -9.03%
on 07/06/26
+1.34 (+2.38%)
since 05/28/26
52-Week
44.12 +30.83%
on 03/30/26
78.48 -26.45%
on 10/08/25
+4.67 (+8.80%)
since 08/28/25

Most Recent Stories

More News
CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026

-Data presented in a late-breaking presentation at the European Society of Cardiology (ESC) Congress 2026-

CRSP : 57.72 (-2.78%)
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results

ZUG, Switzerland and BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the...

CRSP : 57.72 (-2.78%)
CRISPR Therapeutics' Pipeline Progress Must Now Justify What the Balance Sheet Cannot Sustain Much Longer

Barchart Research What to Expect from CRSP Earnings CRSP Generated July 31, 2026 Current Price $47.99 EPS Estimate $$-1.10 Consensus Rating Moderate Buy Average Move 4.07% CRISPR Therapeutics' Pipeline...

CRSP : 57.72 (-2.78%)
Vertex’s Crinetics Deal Balances Growth with Integration Risk

Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals for $10 billion at $85 per share, adding the approved drug PALSONIFY and pipeline candidate Atumelant to expand beyond its cystic fibrosis...

CRSP : 57.72 (-2.78%)
CRNX : 84.84 (-0.01%)
VRTX : 541.69 (-1.07%)
CRISPR Therapeutics Enters 'Second Phase' as CASGEVY Momentum Builds, Pipeline Data Looms

CRISPR Therapeutics (NASDAQ:CRSP) Chief Executive Officer Sam Kulkarni said the company is entering a “second phase” as it moves beyond the initial launch of CASGEVY and prepares for data from multiple...

CRSP : 57.72 (-2.78%)
CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference

ZUG, Switzerland and BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management...

CRSP : 57.72 (-2.78%)
BAC : 62.32 (+1.88%)
CRISPR Therapeutics Approaches Its First Earnings With Casgevy Revenue Actually Flowing Through

Barchart Research What to Expect from CRSP Earnings CRSP Generated May 4, 2026 Current Price $53.58 EPS Estimate $$-1.14 Consensus Rating Moderate Buy Average Move 3.85% CRISPR Therapeutics Approaches...

CRSP : 57.72 (-2.78%)
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

ZUG, Switzerland and BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter...

CRSP : 57.72 (-2.78%)
3 Biotech Stocks That Could Benefit from the Patent Cliff

Biotech M&A is surging ahead of a $300B patent cliff. Here are 3 gene-editing stocks investors are watching as potential acquisition targets

BEAM : 29.32 (-3.81%)
CRSP : 57.72 (-2.78%)
MRK : 148.35 (-0.80%)
BMY : 66.58 (-0.55%)
NTLA : 12.87 (-1.83%)
3 ETFs to Buy Now If You Want to Invest Directly in OpenAI

Cathie Wood’s ARK Invest is giving retail investors a rare shot at OpenAI, bringing pre-IPO AI exposure into ARKK, ARKW, and ARKF

ARKW : 155.19 (-2.09%)
$SPX : 7,711.76 (-0.25%)
CRCL : 87.14 (-7.53%)
COIN : 178.64 (-6.33%)
ARKK : 84.59 (-3.19%)
SHOP : 152.90 (-0.93%)
ARKF : 46.10 (-1.98%)
TSLA : 348.75 (-1.71%)
CRSP : 57.72 (-2.78%)
AMD : 465.58 (-2.33%)
XYZ : 83.57 (-1.51%)
TEM : 64.04 (-9.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

CRISPR Therapeutics AG is a leading gene editing company focused on developing CRISPR/Cas9-based therapeutics. The company is rapidly leveraging its CRISPR/Cas9 gene-editing platform to make therapies for the treatment of hemoglobinopathies, cancer, diabetes and other diseases.

See More

Key Turning Points

3rd Resistance Point 61.30
2nd Resistance Point 60.33
1st Resistance Point 59.03
Last Price 57.72
1st Support Level 56.76
2nd Support Level 55.79
3rd Support Level 54.49

See More

52-Week High 78.48
Fibonacci 61.8% 65.35
Fibonacci 50% 61.30
Last Price 57.72
Fibonacci 38.2% 57.25
52-Week Low 44.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.